1. Novel Artificial Tears Containing Cross-Linked Hyaluronic Acid: An In Vitro Re-Epithelialization Study.
- Author
-
Fallacara A, Vertuani S, Panozzo G, Pecorelli A, Valacchi G, and Manfredini S
- Subjects
- Analysis of Variance, Biomarkers, Cell Line, Cell Survival, Cyclin D1 metabolism, Drug Stability, Dry Eye Syndromes, Epithelium, Corneal drug effects, Humans, Hyaluronic Acid chemistry, Hydrogen-Ion Concentration, Lubricant Eye Drops analysis, Lubricant Eye Drops chemical synthesis, Re-Epithelialization drug effects, Viscosity, Wound Healing drug effects, Hyaluronic Acid analysis, Lubricant Eye Drops chemistry, Lubricant Eye Drops pharmacology
- Abstract
Dry eye syndrome is a common disease which can damage the corneal epithelium. It is treated with eye drops to stimulate tear production and hydrate the corneal surface. The most prescribed artificial tear remedies contain hyaluronic acid (HA), which enhances epithelial wound healing, improving tissue health. To the best of our knowledge, only a few recent studies have investigated cross-linked HA (HA-CL) in eye drops for human applications. This work consists in an in vitro evaluation of the re-epithelialization ability of two different preparations containing a recently synthetized HA cross-linked with urea: 0.02% ( w / v ) HA-CL (solution 1, S1), and 0.4% ( w / v ) HA-CL (solution 2, S2). The study was conducted on both 2D human corneal cells (HCEpiC) and 3D reconstructed tissues of human corneal epithelium (HCE). Viability by 3(4,5-dimethylthiazol-2)2,5-diphenyltetrazolium bromide (MTT) test, pro-inflammatory cytokine release (interleukin-8, IL-8) by ELISA, and morphology by hematoxylin and eosin (HE) staining were evaluated. In addition, to understand the molecular basis of the re-epithelialization properties, cyclin D1 levels were assessed by western blot. The results showed no cellular toxicity, a slight decrease in IL-8 release, and restoration of epithelium integrity when the wounded 3D model was treated with S1 and S2. In parallel, cyclin D1 levels increased in cells treated with both S1 and S2., Competing Interests: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
- Published
- 2017
- Full Text
- View/download PDF